1. Home
  2. BLRX vs KPLT Comparison

BLRX vs KPLT Comparison

Compare BLRX & KPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
  • KPLT
  • Stock Information
  • Founded
  • BLRX 2003
  • KPLT 2012
  • Country
  • BLRX Israel
  • KPLT United States
  • Employees
  • BLRX N/A
  • KPLT N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • KPLT Diversified Commercial Services
  • Sector
  • BLRX Health Care
  • KPLT Consumer Discretionary
  • Exchange
  • BLRX Nasdaq
  • KPLT Nasdaq
  • Market Cap
  • BLRX 17.2M
  • KPLT 97.4M
  • IPO Year
  • BLRX 2011
  • KPLT N/A
  • Fundamental
  • Price
  • BLRX $3.76
  • KPLT $20.96
  • Analyst Decision
  • BLRX Strong Buy
  • KPLT Hold
  • Analyst Count
  • BLRX 2
  • KPLT 1
  • Target Price
  • BLRX $19.00
  • KPLT $10.00
  • AVG Volume (30 Days)
  • BLRX 32.7K
  • KPLT 102.6K
  • Earning Date
  • BLRX 08-14-2025
  • KPLT 11-05-2025
  • Dividend Yield
  • BLRX N/A
  • KPLT N/A
  • EPS Growth
  • BLRX N/A
  • KPLT N/A
  • EPS
  • BLRX N/A
  • KPLT N/A
  • Revenue
  • BLRX $17,251,000.00
  • KPLT $267,101,999.00
  • Revenue This Year
  • BLRX N/A
  • KPLT $22.88
  • Revenue Next Year
  • BLRX N/A
  • KPLT $10.98
  • P/E Ratio
  • BLRX N/A
  • KPLT N/A
  • Revenue Growth
  • BLRX 1.19
  • KPLT 13.04
  • 52 Week Low
  • BLRX $2.30
  • KPLT $5.08
  • 52 Week High
  • BLRX $26.80
  • KPLT $24.34
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 47.80
  • KPLT 59.93
  • Support Level
  • BLRX $3.68
  • KPLT $18.37
  • Resistance Level
  • BLRX $4.11
  • KPLT $23.07
  • Average True Range (ATR)
  • BLRX 0.26
  • KPLT 2.54
  • MACD
  • BLRX 0.03
  • KPLT 0.01
  • Stochastic Oscillator
  • BLRX 36.17
  • KPLT 69.52

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About KPLT Katapult Holdings Inc.

Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.

Share on Social Networks: